Advanced Cell Engineering and 3D Models Services

PDXO 3D Culture in Matrigel. Maintenance and/or expansion of active PDX-derived organoids growing in Matrigel.

PDO and PDXO-PDX derived tumor organoid culture. Generation of tumor organoid models from human patient or PDX tissue sources.

Cryopreserved PDXO distribution. Viably frozen tumor organoid model distribution to investigators.

PDO and PDXO Characterization – Tier 1. Assisted tumor organoid model characterization including STR fingerprinting, biomarker expression, and tumor gene expression.

PDO and PDXO Characterization – Tier 2. Assisted tumor organoid model characterization including cytometer-sorted tumor cell enrichment and stromal cell elimination.

GentleMACS automated tissue dissociation. Tumor dissociation/homogenization instrument operation available to Core users (or assisted use from Core staff).

IVIS bioluminescence imaging instrument. Instrument operation available to Core users independently (with appropriate training) or with assisted use. Instrument can only be used if a reservation has been made with Core staff.

Ovivo. Conversion of 2D cells to 3D structures on CAM. Includes egg incubation, egg preparation, and tumor harvest. Does not include imaging or final report.

Ovotar. Patient Derived Xenograft establishment on CAM. Includes egg incubation, egg preparation, and tumor harvest. Does not include imaging or final report.

OvoQuest. Custom bioassay kit that includes 9 eggs and 2h of tech time. This type of request includes egg incubation, egg preparation, tumor harvest, imaging and report building for 9 eggs. 

Technician Time. Technical assistance. Applies to report building, tissue harvest, brightfield imaging, invasion analysis, angiogenesis analysis, etc.

Genomic Resources. Orders for library clones may be delivered as glycerol stocks or in other formats. For availability of clones for your gene(s) of interest, please send your list of genes (official gene symbols only) to ATC-ACE3MCore@bcm.edu. For pricing information, please visit Pricing page or contact us. Please visit FAQ page for more library-related questions.

Whole-genome human lentiviral CRISPR gRNA library. Pre-made LentiArray CRISPR gRNA vectors (see details here) are available. Please contact us at ATC-ACE3MCore@bcm.edu for details.

Whole-genome human and mouse shRNA libraries. The human and mouse mir30-based lentiviralp GIPZshRNA libraries contain ~140,000 and ~90,000 individual shRNA clones respectively targeting the entire human and mouse genome. shRNA positive control clones (GAPDH and EG5) and negative control clones (non-silencing and empty vectors) are also available. Please visit https://dharmacon.horizondiscovery.com/rnai/screening-libraries/shrna/gipz/#all for details.

Please contact us for assembling custom shRNA or CRISPR gRNA libraries, such as those that target a particular signaling pathway or activity.

Whole-genome human and mouse cDNA libraries. The Human ORFeome 8.1 collection is the Gateway-compatible human ORFeome library created by the Center for Cancer Systems Biology of the Dana-Farber Cancer Institute and contains >17,000 clones that represent >12,000 genes. These open reading frames (ORFs) (native stop codons removed) can be easily shuttled into Gateway-compatible destination vectors either individually or as arrayed libraries in multi-well plates. The core has several lentiviral destination vectors and can provide gateway cloning service.  Please visit http://horfdb.dfci.harvard.edu/ for more information.

The Mouse MGC cDNA Library contains mouse MGC cDNAs (IRAV+IRAW). Please see http://mgc.nci.nih.gov/ for more details.

sgRNA/shRNA/cDNA-Expressing Cell Line(s) and Lentiviral Stocks. The ACE-3M core will establish cells (provided by the user) that express the shRNA(s)/cDNA of interest (from our collection or custom lentiviral expression vectors). Lentivirus can be made by the ACE-3M core for sgRNA, shRNA, or a construct of your interest.

CRISPR/Cas9-mediated gene editing services.
The ACE-3M Core is equipped to work with investigators to engineer genome modifications in a variety of cell lines using CRISPR/Cas9 technologies.  We have successfully created cells with intended genomic deletions, insertions, gene disruption (KO), and SNP mutations (KI).